

Warren J Strittmatter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11657534/publications.pdf>

Version: 2024-02-01

57
papers

5,407
citations

117625

34
h-index

155660

55
g-index

57
all docs

57
docs citations

57
times ranked

5510
citing authors

#	ARTICLE	IF	CITATIONS
1	Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. <i>Nature Neuroscience</i> , 2002, 5, 731-736.	14.8	925
2	Apolipoprotein E and Alzheimer's Disease. <i>Annual Review of Neuroscience</i> , 1996, 19, 53-77.	10.7	429
3	Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. <i>Nature Medicine</i> , 1996, 2, 347-350.	30.7	429
4	Hypothesis: Microtubule Instability and Paired Helical Filament Formation in the Alzheimer Disease Brain Are Related to Apolipoprotein E Genotype. <i>Experimental Neurology</i> , 1994, 125, 163-171.	4.1	388
5	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. <i>PLoS Genetics</i> , 2009, 5, e1000373.	3.5	383
6	Preliminary Report of a Genetic Basis for Cognitive Decline After Cardiac Operations 11The members of the Neurologic Outcome Research Group of the Duke Heart Center are listed in Appendix A.. <i>Annals of Thoracic Surgery</i> , 1997, 64, 715-720.	1.3	291
7	Apolipoprotein E Is Localized to the Cytoplasm of Human Cortical Neurons: A Light and Electron Microscopic Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 1994, 53, 535-544.	1.7	189
8	Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display Screening. <i>Journal of Biological Chemistry</i> , 2000, 275, 10437-10442.	3.4	166
9	Apolipoprotein E Is Present in Hippocampal Neurons without Neurofibrillary Tangles in Alzheimer's Disease and in Age-Matched Controls. <i>Experimental Neurology</i> , 1994, 128, 13-26.	4.1	141
10	Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in <i>Drosophila</i> . <i>Human Molecular Genetics</i> , 2003, 12, 1253-1259.	2.9	122
11	Genome-Wide Scan of Copy Number Variation in Late-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 69-77.	2.6	118
12	Impairment of the Bloodâ€Nerve and Bloodâ€Brain Barriers in Apolipoprotein E Knockout Mice. <i>Experimental Neurology</i> , 2001, 169, 13-22.	4.1	102
13	In vitro effects of polyglutamine tracts on Ca ²⁺ -dependent depolarization of rat and human mitochondria: relevance to Huntingtonâ€™s disease. <i>Archives of Biochemistry and Biophysics</i> , 2003, 410, 1-6.	3.0	94
14	Generation of Neuronal Intranuclear Inclusions by Polyglutamine-GFP: Analysis of Inclusion Clearance and Toxicity as a Function of Polyglutamine Length. <i>Journal of Neuroscience</i> , 1999, 19, 705-715.	3.6	89
15	Polyglutamine Domains Are Substrates of Tissue Transglutaminase: Does Transglutaminase Play a Role in Expanded CAG/Polyâ€Q Neurodegenerative Diseases?. <i>Journal of Neurochemistry</i> , 1997, 69, 431-434.	3.9	84
16	Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. <i>Neuroscience Letters</i> , 1994, 182, 55-58.	2.1	83
17	The role of apolipoprotein E in Alzheimerâ€™s disease: pharmacogenomic target selection. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1502, 85-94.	3.8	83
18	Differential Binding of Apolipoprotein E Isoforms to Tau and Other Cytoskeletal Proteins. <i>Experimental Neurology</i> , 1996, 138, 252-260.	4.1	80

#	ARTICLE	IF	CITATIONS
19	Crosslinking of Apolipoprotein E by Products of Lipid Peroxidation. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 202-210.	1.7	80
20	Apolipoprotein E Binds to and Potentiates the Biological Activity of Ciliary Neurotrophic Factor. <i>Journal of Neuroscience</i> , 1997, 17, 6114-6121.	3.6	72
21	Apolipoprotein E and Neuromuscular Disease. <i>Archives of Neurology</i> , 2000, 57, 1561-5.	4.5	68
22	Molecular biology of apolipoprotein E. <i>Current Opinion in Lipidology</i> , 2002, 13, 119-123.	2.7	66
23	Oligomerization of Expanded-Polyglutamine Domain Fluorescent Fusion Proteins in Cultured Mammalian Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 238, 599-605.	2.1	64
24	Risky apolipoprotein in brain. <i>Nature</i> , 1994, 372, 45-46.	27.8	62
25	Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice. <i>Neurobiology of Aging</i> , 2007, 28, 1853-1862.	3.1	61
26	ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. <i>Neuroscience Letters</i> , 1995, 192, 209-212.	2.1	56
27	Interaction of Apolipoprotein E with Laminin Increases Neuronal Adhesion and Alters Neurite Morphology. <i>Experimental Neurology</i> , 1995, 136, 251-257.	4.1	53
28	Toxicity of expanded polyglutamine-domain proteins in Escherichia coli. <i>FEBS Letters</i> , 1996, 399, 135-139.	2.8	44
29	Expanded polyglutamine stretches form an "aggresome"™. <i>Neuroscience Letters</i> , 2002, 323, 215-218.	2.1	41
30	Novel Large Apolipoprotein E-Containing Lipoproteins of Density 1.006-1.060 g/ml in Human Cerebrospinal Fluid. <i>Journal of Neurochemistry</i> , 1998, 70, 1235-1240.	3.9	41
31	Apolipoprotein E and brain injury: implications for children. <i>Developmental Medicine and Child Neurology</i> , 2005, 47, 64-70.	2.1	41
32	Peripheral Sensory Nerve Defects in Apolipoprotein E Knockout Mice. <i>Experimental Neurology</i> , 1998, 153, 156-163.	4.1	39
33	Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 607-613.	2.1	37
34	Old Drug, New Hope for Alzheimer's Disease. <i>Science</i> , 2012, 335, 1447-1448.	12.6	36
35	ApoE genotype-specific inhibition of apoptosis. <i>Journal of Lipid Research</i> , 2003, 44, 1566-1573.	4.2	35
36	Inhibition of Protein Misfolding/Aggregation Using Polyglutamine Binding Peptide QBP1 as a Therapy for the Polyglutamine Diseases. <i>Neurotherapeutics</i> , 2013, 10, 440-446.	4.4	30

#	ARTICLE	IF	CITATIONS
37	Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms. <i>Biochemical Society Symposia</i> , 2001, 67, 101-109.	2.7	29
38	Bathing the brain. <i>Journal of Clinical Investigation</i> , 2013, 123, 1013-1015.	8.2	28
39	Avid Binding of $\hat{1}^2$ A Amyloid Peptide to Its Own Precursor. <i>Experimental Neurology</i> , 1993, 122, 327-334.	4.1	27
40	Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 1200-1206.	2.1	26
41	Glyceraldehyde 3-Phosphate Dehydrogenase Abnormality in Metabolically Stressed Huntington Disease Fibroblasts. <i>Developmental Neuroscience</i> , 1998, 20, 462-468.	2.0	25
42	Expanded Polyglutamine Domain Proteins Bind Neurofilament and Alter the Neurofilament Network. <i>Experimental Neurology</i> , 1999, 155, 195-203.	4.1	21
43	APOE4 -VLDL Inhibits the HDL-Activated Phosphatidylinositol 3-Kinase/Akt Pathway via the Phosphoinositol Phosphatase SHIP2. <i>Circulation Research</i> , 2006, 99, 829-836.	4.5	21
44	The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases. <i>Journal of Amino Acids</i> , 2011, 2011, 1-10.	5.8	20
45	Human apolipoprotein E accelerates microtubule polymerization in vitro. <i>Neuroscience Letters</i> , 1998, 245, 105-108.	2.1	14
46	Apolipoprotein E and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2006, 924, 91-92.	3.8	13
47	Optimization of a Polyglutamine Aggregation Inhibitor Peptide (QBP1) Using a Thioflavin T Fluorescence Assay. <i>Assay and Drug Development Technologies</i> , 2007, 5, 629-636.	1.2	11
48	Polyglutamine Domain Proteins with Expanded Repeats Bind Neurofilament, Altering the Neurofilament Network. <i>Annals of the New York Academy of Sciences</i> , 1999, 893, 192-201.	3.8	10
49	Binding of IgG to amyloid $\hat{1}^2$ A4 peptide via the heavy-chain hinge region with preservation of antigen binding. <i>Journal of Neuroimmunology</i> , 1993, 48, 199-203.	2.3	8
50	High-fat/high-cholesterol diet promotes a S1P receptor-mediated antiapoptotic activity for VLDL. <i>Journal of Lipid Research</i> , 2007, 48, 806-815.	4.2	8
51	Alzheimer's disease: the new promise. <i>Journal of Clinical Investigation</i> , 2012, 122, 1191-1191.	8.2	8
52	Apolipoprotein E: Emerging Story in the Pathogenesis of Alzheimer's Disease. <i>Neuroscientist</i> , 1995, 1, 298-306.	3.5	7
53	Inhibition of $\hat{1}^{\pm}$ -ketoglutarate-and pyruvate dehydrogenase complexes in E. coli by a glutathione S-transferase containing a pathological length poly-Q domain: A possible role of energy deficit in neurological diseases associated with poly-Q expansions?. <i>Age</i> , 1998, 21, 25-30.	3.0	3
54	Phage Display Screening for Peptides that Inhibit Polyglutamine Aggregation. <i>Methods in Enzymology</i> , 2006, 413, 253-273.	1.0	3

#	ARTICLE	IF	CITATIONS
55	Reply to "A role for GAPDH in apoptosis and neurodegeneration" Nature Medicine, 1996, 2, 610-610.	30.7	2
56	Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3081-3081.	1.4	1
57	Isoform-Specific Metabolism of Apolipoprotein E: Implications for Alzheimer "s Disease. , 1997, , 47-53.		0